QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
NASDAQ:KRTX

Karuna Therapeutics - KRTX Stock Forecast, Price & News

$195.69
+3.54 (+1.84%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$189.45
$196.18
50-Day Range
$189.25
$236.82
52-Week Range
$92.26
$278.25
Volume
225,182 shs
Average Volume
266,107 shs
Market Capitalization
$6.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$262.75

Karuna Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
34.3% Upside
$262.75 Price Target
Short Interest
Bearish
6.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Karuna Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$11.47 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($8.78) to ($9.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

635th out of 1,029 stocks

Pharmaceutical Preparations Industry

312th out of 504 stocks

KRTX stock logo

About Karuna Therapeutics (NASDAQ:KRTX) Stock

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KRTX Stock News Headlines

The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
SVB Securities Reaffirms Their Buy Rating on Karuna Therapeutics (KRTX)
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Analyst Expectations for Karuna Therapeutics's Future
KRTX.A - | Stock Price & Latest News | Reuters
What 5 Analyst Ratings Have To Say About Karuna Therapeutics
5 Analysts Have This to Say About Karuna Therapeutics
Karuna: Acquisition Prospects Thin With CEO Change
Karuna Therapeutics drops 12% after CEO change
Karuna Therapeutics: Q3 Earnings Insights
See More Headlines
Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KRTX Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$262.75
High Stock Price Forecast
$330.00
Low Stock Price Forecast
$183.00
Forecasted Upside/Downside
+34.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

Net Income
$-143,800,000.00
Pretax Margin
-537.65%

Debt

Sales & Book Value

Annual Sales
$36.96 million
Book Value
$16.95 per share

Miscellaneous

Free Float
28,796,000
Market Cap
$6.72 billion
Optionable
Not Optionable
Beta
1.18

Key Executives

  • Andrew Miller
    Chief Operating Officer
  • Troy A. IgnelziTroy A. Ignelzi
    Chief Financial Officer & Secretary
  • Stephen BrannanStephen Brannan
    Chief Medical Officer
  • Ronald Marcus
    Senior Vice President-Medical
  • Inder Kaul
    Vice President-Clinical Development













KRTX Stock - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRTX shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price forecast for 2023?

15 equities research analysts have issued 12-month target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $183.00 to $330.00. On average, they expect the company's share price to reach $262.75 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2023?

Karuna Therapeutics' stock was trading at $196.50 at the beginning of the year. Since then, KRTX shares have decreased by 0.4% and is now trading at $195.69.
View the best growth stocks for 2023 here
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.47) by $0.25.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Clarius Group LLC (0.32%), Emerald Advisers LLC (0.29%), TD Asset Management Inc (0.29%), Emerald Mutual Fund Advisers Trust (0.23%), New York State Common Retirement Fund (0.20%) and Catalyst Private Wealth LLC (0.06%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $195.69.

How much money does Karuna Therapeutics make?

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $6.72 billion and generates $36.96 million in revenue each year. The company earns $-143,800,000.00 in net income (profit) each year or ($7.44) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.

This page (NASDAQ:KRTX) was last updated on 2/7/2023 by MarketBeat.com Staff